查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
T細胞治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按模式、治療類型、適應症和地理位置
市場調查報告書
商品編碼
1362429

T細胞治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按模式、治療類型、適應症和地理位置

T Cell Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type, Indication, and Geography
出版日期: | 出版商: The Insight Partners | 英文 138 Pages | 訂單完成後即時交付

價格

依據「T細胞治療市場預測(2020 -2030年)、全球和地區佔有率、趨勢和成長機會分析 - 按模式、治療類型和適應症」的新研究，T細胞治療市場規模估值為2022年為27.540億美元，預計到2030年將達到90.3501億美元。預計2020-2030年年複合成長率為16.0%。

T細胞療法是最有前景的癌症治療方法之一，每年都會進行越來越多的臨床前和臨床研究以增加其應用。 CAR T細胞療法也引起了腫瘤學家和學者的興趣。全球癌症負擔日益加重以及 T細胞療法獲批數量不斷增加，推動了 T細胞療法市場的成長。此外，臨床試驗中汽車 T細胞療法數量的增加預計將推動未來幾年 T細胞療法市場的成長。

目前 CAR T細胞療法前景廣闊，擁有多種藥物批准、豐富的產品線以及許多進行的臨床試驗。 CAR T細胞療法的管道處於臨床開發的不同階段；主要製藥公司努力推進 CAR T細胞治療競爭領域的管道空間和未來成長潛力。

2022年11月，Peter MacCallum 癌症中心和Cartherics Pty Ltd 簽訂了合作開發計畫協議(CDPA)，開發Cartherics 專有的自體CAR T細胞療法(CTH-001)，用於治療皮膚T細胞淋巴瘤(CTCL)。合作研究的關鍵面向是建立CTH-001的臨床規模生產並進行I期臨床試驗。最初將招募 6 名難治性 CTCL 患者。

JW Therapeutics 藥物 JWCAR029 是一款針對 CD19 的 CAR T細胞產品，目的是治療晚期淋巴瘤和白血病。該分子目前正處於開發的第二階段。 JWCAR029 最初被研究用於治療 B 細胞惡性腫瘤，重點是復發性和難治性 DLBCL。

吉利德科學公司的藥物 KTE-X19 是一種研究的自體 CD19 CAR T細胞療法。該藥物採用 XLP 製程生產，包括 T細胞選擇和淋巴細胞富集。研究 KTE-X19 的某些 B 細胞惡性腫瘤需要淋巴細胞富集。 KTE-X19目前進行治療成人和兒童急性淋巴性白血病的II期臨床試驗。 FDA 已批准 Brexucabtagene autoleucel(以前稱為 KTE-X19；Tecartus)用於治療患有復發或難治性套細胞淋巴瘤(MCL)的成年患者。

ZUMA-3 是一項1/2 期研究，評估KTE-X19(一種自體抗CD19 CAR T細胞療法)治療成人復發/難治性(R/R)B 細胞急性淋巴細胞白血病(B-ALL)的效果。

Descartes-11 是一種 mRNA CAR T細胞療法，已進入針對新診斷的高風險多發性骨髓瘤(MM)患者的 II 期臨床試驗。 Descartes-11 可瞬時表達 CAR T細胞分子，並避免這些治療藥物的一些特徵毒性。一項針對 18 名患者的 I 期研究(NCT03994705)已經開展，結果顯示沒有證據表明細胞激素釋放症候群或神經毒性不良事件通常與 CAR T細胞治療相關。

因此，上述CAR-T細胞療法的管線正成為T細胞療法市場的新趨勢。

按形式，T細胞治療市場洞察

根據形式，T細胞治療市場分為研究型和商業化型。2022年，商業化細分市場佔據更大的市場佔有率。此外，預計同一細分市場在預測期內將成長最快。產品發布的增加以及人們對 T細胞治療癌症治療益處的認知的提高，推動了商業化領域的成長。

按治療類型分類，基於 T細胞治療市場的見解

根據治療類型，T細胞治療市場分為 CAR T細胞治療和基於 T細胞受體(TCR)的治療。2022年，CAR T細胞治療領域佔據更大的市場。此外，同一細分市場在預測期內將以顯著的速度成長。在嵌合抗原受體(CAR)T細胞治療技術中，從患者身上獲得的T細胞經過人工生物工程改造，表達能夠辨識並附著在腫瘤細胞上的CAR。這些公司進行策略發展，例如合作、擴張、協議、夥伴關係以及 CAR T細胞領域營運公司推出的新產品，推動 T細胞治療市場的成長。例如，2022年，FDA批准了Janssen Biotech, Inc.生產的CARVYKTI。CARVYKTI是一種名為CAR-T的療法，代表嵌合抗原受體T細胞。 CARVYKTI(ciltacabtagene autoleucel)是一種用於治療患有骨髓癌(稱為多發性骨髓瘤)的成年患者的治療方法。 CARVYKTI 治療經過四種或更多種前線治療後復發或難治性多發性骨髓瘤的成年患者，包括蛋白酶體抑制劑、免疫調節劑和抗 CD38 單株抗體。

世界衛生組織(WHO)、歐洲癌症患者聯盟和國家癌症研究所是在準備 T細胞治療市場報告時提到的一些主要的主要和次要來源。

目錄

第1章 簡介

  • Insight Partners 研究報告指南
  • 市場區隔

第2章 執行摘要

  • 重要見解
  • T細胞治療市場(依地理位置)

第3章 研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第4章 T細胞治療市場格局

  • 概述
  • PEST分析
    • 全球PEST分析

第5章 T細胞治療市場 - 主要產業動態

  • 市場促進因素：
    • 全球癌症負擔日益加重
    • T細胞療法獲批數量不斷增加
  • 市場限制
    • CAR T細胞療法的副作用
  • 市場機會
    • T細胞治療投資不斷增加
  • 未來的趨勢
    • 臨床試驗中 CAR T細胞療法的數量不斷增加
  • 影響分析：

第6章 T細胞治療市場 - 全球市場分析

  • T細胞治療市場收入，2022 -2030

第7章 全球 T細胞治療市場 - 收入和2030年預測 - 按方式

  • 概述
  • 2022年和2030年 T細胞治療市場收入佔有率(按方式)(%)
  • 研究
  • 商業化

第8章 全球 T細胞治療市場 -2030年收入和預測 - 按治療類型

  • 概述
  • 2022年和2030年按治療類型分類的 T細胞治療市場收入佔有率(%)
  • CAR T細胞療法
  • 基於 T細胞受體(TCR)

第9章 全球 T細胞治療市場 - 收入和2030年預測 - 按指標

  • 概述
  • 2022年和2030年按適應症分類的 T細胞治療市場收入佔有率(%)
  • 血液系統惡性腫瘤
  • 實體腫瘤

第10章 T細胞治療市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 以色列
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西

第11章 T細胞治療市場-產業格局

  • 概述
  • T細胞治療市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第12章 公司簡介

  • Immunocore Holdings Plc
  • Legend Biotech Corp
  • Janssen Global Services LLC
  • Gilead Sciences Inc
  • Bristol-Myers Squibb Co
  • Bluebird Bio Inc
  • Novartis AG
  • JW(Cayman)Therapeutics Co Ltd
  • Cartesian Therapeutics Inc
  • Innovent Biologics Inc

第13章 附錄

  • 關於我們
  • 專業術語
Product Code: TIPRE00024331

According to our new research study on "T Cell Therapy Market Forecast (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis - by Modality, Therapy Type, and Indication," the T cell therapy market size was valued at US$ 2,754.00 million in 2022 and is expected to reach US$ 9,035.01 million by 2030. It is estimated to register a CAGR of 16.0% during 2020-2030.

One of the most promising procedures of cancer treatment is T cell therapy, and every year, an increasing number of pre-clinical and clinical research is being conducted to increase its application. CAR T cell therapy has also generated interest among oncologists and academics. The growing burden of cancer worldwide and an increasing number of T cell therapy approvals drive the growth of the T cell therapy market. Also, rising number of car t-cell therapies in clinical trials is expected to fuel T cell therapy market growth in the coming years.

The current landscape for CAR T-cell therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.

In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics' proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL.

JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.

Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL).

ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).

Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity-adverse events commonly associated with CAR T-cell treatment.

Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the T cell therapy market.

By Modality, T Cell Therapy Market-Based Insights

Based on modality, the T cell therapy market is segmented into research and commercialized. In 2022, the commercialized segment held the larger share of the market. Moreover, the same segment is expected to grow fastest during the forecast period. An increase in product launches and a rise in awareness about the benefits of T cell therapy for cancer treatment fueling the growth of the commercialized segment.

By Therapy Type, T Cell Therapy Market -Based Insights

Based on therapy type, the T cell therapy market is bifurcated into CAR T cell therapy and T cell receptor (TCR)-based. In 2022, the CAR T cell therapy segment held the larger share of the market. Moreover, the same segment will grow at a significant growth rate during the forecast period. In the chimeric antigen receptor (CAR) T cell therapy technique, T cells obtained from patients are artificially bioengineered to express CARs that can identify and attach to the tumor cells. The companies are entering into strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches by companies operating in the CAR T cell segment, fueling the T cell therapy market growth. For instance, in 2022, FDA approved CARVYKTI manufactured by Janssen Biotech, Inc. CARVYKTI is a kind of therapy called CAR-T-which stands for chimeric antigen receptor T cell. CARVYKTI (ciltacabtagene autoleucel) is a treatment used for adult patients with bone marrow cancer called multiple myeloma. CARVYKTI treats adult patients with relapsed or refractory multiple myeloma after four or more former lines of therapy, comprising a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The World Health Organization (WHO), the European Cancer Patient Coalition, and the National Cancer Institute are a few of the major primary and secondary sources referred to while preparing the report on the T cell therapy market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the T cell therapy market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global T cell therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global T cell therapy market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 T Cell Therapy Market, by Geography (US$ Million)

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. T Cell Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 Global PEST Analysis

5. T Cell Therapy Market - Key Industry Dynamics

  • 5.1 Market Drivers:
    • 5.1.1 Growing Burden of Cancer Worldwide
    • 5.1.2 Increasing Number of T-Cell Therapy Approvals
  • 5.2 Market Restraints
    • 5.2.1 Side-effects of CAR T-Cell Therapy
  • 5.3 Market Opportunities
    • 5.3.1 Growing Investment in T-Cell Therapy
  • 5.4 Future Trends
    • 5.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
  • 5.5 Impact Analysis:

6. T Cell Therapy Market - Global Market Analysis

  • 6.1 T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

7. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality

  • 7.1 Overview
  • 7.2 T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
  • 7.3 Research
    • 7.3.1 Overview
    • 7.3.2 Research: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Commercialized
    • 7.4.1 Overview
    • 7.4.2 Commercialized: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

  • 8.1 Overview
  • 8.2 T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
  • 8.3 CAR T-cell Therapy
    • 8.3.1 Overview
    • 8.3.2 CAR T-cell Therapy: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 T-cell Receptor (TCR)-based
    • 8.4.1 Overview
    • 8.4.2 T-cell Receptor (TCR)-based: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

  • 9.1 Overview
  • 9.2 T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
  • 9.3 Hematologic Malignancies
    • 9.3.1 Overview
    • 9.3.2 Hematologic Malignancies: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
    • 9.3.3 Global T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
  • 9.4 Solid Tumor
    • 9.4.1 Overview
    • 9.4.2 Solid Tumor: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

10. T Cell Therapy Market - Geographical Analysis

  • 10.1 North America T Cell Therapy Market, Revenue and Forecast To 2030
    • 10.1.1 Overview
    • 10.1.2 North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.1.3 North America: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    • 10.1.4 North America: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    • 10.1.5 North America: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
      • 10.1.5.1 North America: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.1.5.2 North America T Cell Therapy Market, by Country
      • 10.1.5.3 US
        • 10.1.5.3.1 US T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.5.3.2 US: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.1.5.3.3 US: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.1.5.3.4 US: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.5.3.4.1 US: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.1.5.4 Canada
        • 10.1.5.4.1 Canada T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.5.4.2 Canada: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.1.5.4.3 Canada: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.1.5.4.4 Canada: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.5.4.4.1 Canada: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.1.5.5 Mexico
        • 10.1.5.5.1 Mexico T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.5.5.2 Mexico: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.1.5.5.3 Mexico: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.1.5.5.4 Mexico: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.5.5.4.1 Mexico: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  • 10.2 Europe T Cell Therapy Market, Revenue and Forecast to 2030
    • 10.2.1 Overview
    • 10.2.2 Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.2.3 Europe: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    • 10.2.4 Europe: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    • 10.2.5 Europe: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
      • 10.2.5.1 Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.2.5.2 Europe T Cell Therapy Market, by Country
      • 10.2.5.3 UK
        • 10.2.5.3.1 UK T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.5.3.2 UK: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.2.5.3.3 UK: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.5.3.4 UK: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.5.3.4.1 UK: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.2.5.4 Germany
        • 10.2.5.4.1 Germany T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.5.4.2 Germany: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.2.5.4.3 Germany: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.5.4.4 Germany: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.5.4.4.1 Germany: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.2.5.5 France
        • 10.2.5.5.1 France T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.5.5.2 France: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.2.5.5.3 France: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.5.5.4 France: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.5.5.4.1 France: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.2.5.6 Italy
        • 10.2.5.6.1 Italy T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.5.6.2 Italy: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.2.5.6.3 Italy: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.5.6.4 Italy: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.5.6.4.1 Italy: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.2.5.7 Spain
        • 10.2.5.7.1 Spain T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.5.7.2 Spain: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.2.5.7.3 Spain: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.5.7.4 Spain: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.5.7.4.1 Spain: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.2.5.8 Rest of Europe
        • 10.2.5.8.1 Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.5.8.2 Rest of Europe: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.2.5.8.3 Rest of Europe: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.5.8.4 Rest of Europe: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.5.8.4.1 Rest of Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  • 10.3 Asia Pacific T Cell Therapy Market, Revenue and Forecast to 2030
    • 10.3.1 Overview
    • 10.3.2 Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.3.3 Asia Pacific: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    • 10.3.4 Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    • 10.3.5 Asia Pacific: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
      • 10.3.5.1 Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.3.5.2 Asia Pacific T Cell Therapy Market, by Country
      • 10.3.5.3 China
        • 10.3.5.3.1 China T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.5.3.2 China: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.3.5.3.3 China: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.5.3.4 China: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.5.3.4.1 China: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.3.5.4 Japan
        • 10.3.5.4.1 Japan T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.5.4.2 Japan: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.3.5.4.3 Japan: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.5.4.4 Japan: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.5.4.4.1 Japan: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.3.5.5 Australia
        • 10.3.5.5.1 Australia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.5.5.2 Australia: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.3.5.5.3 Australia: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.5.5.4 Australia: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.5.5.4.1 Australia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.3.5.6 South Korea
        • 10.3.5.6.1 South Korea T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.5.6.2 South Korea: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.3.5.6.3 South Korea: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.5.6.4 South Korea: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.5.6.4.1 South Korea: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.3.5.7 Rest of Asia Pacific
        • 10.3.5.7.1 Rest of Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.5.7.2 Rest of Asia Pacific: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.3.5.7.3 Rest of Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.5.7.4 Rest of Asia Pacific: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.5.7.4.1 Rest of Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  • 10.4 Middle East & Africa T Cell Therapy Market, Revenue and Forecast to 2030
    • 10.4.1 Overview
    • 10.4.2 Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.4.3 Middle East & Africa: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    • 10.4.4 Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    • 10.4.5 Middle East & Africa: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
      • 10.4.5.1 Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.4.5.2 Middle East & Africa T Cell Therapy Market, by Country
      • 10.4.5.3 Saudi Arabia
        • 10.4.5.3.1 Saudi Arabia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.3.2 Saudi Arabia: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.4.5.3.3 Saudi Arabia: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.4.5.3.4 Saudi Arabia: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.4.5.3.4.1 Saudi Arabia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.4.5.4 Israel
        • 10.4.5.4.1 Israel T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.4.2 Israel: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.4.5.4.3 Israel: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.4.5.4.4 Israel: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.4.5.4.4.1 Israel: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.4.5.5 Rest of Middle East & Africa
        • 10.4.5.5.1 Rest of Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.5.2 Rest of Middle East & Africa: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.4.5.5.3 Rest of Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.4.5.5.4 Rest of Middle East & Africa: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.4.5.5.4.1 Rest of Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  • 10.5 South & Central America T Cell Therapy Market, Revenue and Forecast to 2030
    • 10.5.1 Overview
    • 10.5.2 South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.5.2.1 Brazil
        • 10.5.2.1.1 Brazil T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.2.1.2 Brazil: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.5.2.1.3 Brazil: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.5.2.1.4 Brazil: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.5.2.1.4.1 Brazil: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)

11. T Cell Therapy Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in T Cell Therapy Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Immunocore Holdings Plc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Legend Biotech Corp
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Janssen Global Services LLC
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Gilead Sciences Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Bristol-Myers Squibb Co
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Bluebird Bio Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Novartis AG
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 JW (Cayman) Therapeutics Co Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Cartesian Therapeutics Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Innovent Biologics Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. T Cell Therapy Market Segmentation
  • Table 2. Global T Cell Therapy Market, by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. North America T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. North America T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. North America T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. North America T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. US T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. US T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. US T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. US T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Canada T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Canada T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Canada T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Canada T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. Mexico T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. Mexico T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. Mexico T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. Mexico T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 21. Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 22. Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. UK T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. UK T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 25. UK T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 26. UK T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 27. Germany T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 28. Germany T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 29. Germany T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 30. Germany T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 31. France T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 32. France T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 33. France T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 34. France T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 35. Italy T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 36. Italy T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 37. Italy T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 38. Italy T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 39. Spain T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 40. Spain T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 41. Spain T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 42. Spain T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 43. Rest of Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 44. Rest of Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 45. Rest of Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 46. Rest of Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 47. FDA-Approved Autologous CAR T-Cell Therapies Registered in Asia Pacific
  • Table 48. Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 49. Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 50. Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 51. Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 52. China T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 53. China T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 54. China T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 55. China T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 56. Japan T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 57. Japan T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 58. Japan T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 59. Japan T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 60. Australia T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 61. Australia T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 62. Australia T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 63. Australia T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 64. South Korea T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 65. South Korea T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 66. South Korea T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 67. South Korea T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 68. Rest of Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 69. Rest of Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 70. Rest of Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 71. Rest of Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 72. Middle East & Africa T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 73. Middle East & Africa T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 74. Middle East & Africa T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 75. Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 76. Saudi Arabia T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 77. Saudi Arabia T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 78. Saudi Arabia T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 79. Saudi Arabia T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 80. Israel T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 81. Israel T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 82. Israel T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 83. Israel T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 84. Rest of Middle East & Africa T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 85. Rest of Middle East & Africa T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 86. Rest of Middle East & Africa T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 87. Rest of Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 88. Brazil T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 89. Brazil T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 90. Brazil T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 91. Brazil T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 92. Recent Organic Growth Strategies in T Cell Therapy Market
  • Table 93. Recent Inorganic Growth Strategies in the T Cell Therapy Market
  • Table 94. Glossary of Terms, T Cell Therapy Market

List Of Figures

  • Figure 1. T Cell Therapy Market Segmentation, By Geography
  • Figure 2. Global - PEST Analysis
  • Figure 3. T Cell Therapy Market - Key Industry Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
  • Figure 6. T Cell Therapy Market Revenue, Geography (US$ Mn), 2022 - 2030
  • Figure 7. T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
  • Figure 8. Research: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Commercialized: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
  • Figure 11. CAR T-cell Therapy: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. T-cell Receptor (TCR)-based: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
  • Figure 14. Hematologic Malignancies: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Solid Tumor: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. North America: T Cell Therapy Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 17. North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 18. North America T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 19. US T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 20. Canada T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 21. Mexico T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. Europe T Cell Therapy Market, by Key Country - Revenue, 2022 ($Mn)
  • Figure 23. Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 24. Europe T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 25. UK T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 26. Germany T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 27. France T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 28. Italy T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 29. Spain T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 30. Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 31. Asia Pacific T Cell Therapy Market, by Key Country - Revenue, 2022 ($Mn)
  • Figure 32. Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 33. Asia Pacific T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 34. China T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 35. Japan T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 36. Australia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 37. South Korea T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 38. Rest of Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 39. Middle East & Africa T Cell Therapy Market, by Key Country - Revenue, 2022
  • Figure 40. Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 41. Middle East & Africa T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 42. Saudi Arabia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 43. Israel T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 44. Rest of Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 45. South & Central America T Cell Therapy Market, by Key Country - Revenue, 2022 ($Mn)
  • Figure 46. South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 47. Brazil T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 48. Pre & Post Covid-19 Impact
  • Figure 49. Growth Strategies in T Cell Therapy Market